Sustaining Biotech Buzz in Lay Terms – Are You Up to the Challenge?

When the government and a private biotech firm recently announced that scientists had mapped out a working draft of the human DNA code, biotech was cast into a whole new
league of elevated consumer recognition. But for two key stakeholder groups - patient advocacy organizations and investor audiences - the milestone was old news.